2023

CVP BioSpain sponsor´s 2023, one of the Europe´s largest events
26/09/2023

From September 26th to 28th, Barcelona, a hub of healthcare innovation in Europe, will host BIOSPAIN The vibrant city of Barcelona... Read More
Artax Biopharma Announces Positive Phase 1 Results for AX-158
07/06/2023

Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization for Biologic CAR T-Cell Engager ALETA-001. Aleta’s lead program, ALETA-001 has clinical support from... Read More
Minoryx gains FDA approval to patients with cALD
31/05/2023

Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy US trial with leriglitazone to... Read More
ARTHEx Biotech Announces Closing of €42 M Series B Financing
03/05/2023

ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1... Read More
Minoryx presents positive interim results from NEXUS registration study
25/04/2023

Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD) Initial evidence... Read More
Dr. Robert Armstrong joins as new partner and Columbus opens Boston office
27/03/2023

Columbus Venture Partners opens an office in Boston with the addition of Dr. Robert Armstrong as a new partner of the... Read More
Integra Therapeutics acquires CRISPR licence from CIC nanoGUNE
04/01/2023

2.6 billion-year-old ancestors of the CRISPR gene-editing tool are resurrected An international study led by Spanish scientists has deciphered the origin... Read More